RxDoctor Payments Data

Ashley Thorsell, MD

Endocrinology, Diabetes & Metabolism · Santa Barbara, CANPI 1013146364

Payments from drug & device makers

$138,890in general payments, 2019–2025

Across 221 payments — averaging $628.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Diabetes Care, Inc.$83K
  • Abbott$44K
  • Insulet Corporation$8K
  • Novo Nordisk$500
  • Mannkind Corporation$456
  • Medtronic$378
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$3002%
  • Speaking & faculty fees$8,01466%
  • Food & beverage$3,50729%
  • Education$2782%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,890 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$110,271
Medicare patients
324
Services billed
7,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$229,218
Synjardy XrEmpagliflozin/Metformin Hcl117$127,604
TrulicityDulaglutide62$89,351
RybelsusSemaglutide60$88,498
JardianceEmpagliflozin82$88,430
MounjaroTirzepatide80$83,122
Tresiba Flextouch U-100Insulin Degludec51$34,687
Xigduo XrDapaglifloz Propaned/Metformin33$34,159
Teriparatide12$31,074
FarxigaDapagliflozin Propanediol24$26,194
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$24,731
JanuviaSitagliptin Phosphate12$19,784
Fiasp FlextouchInsulin Aspart (Niacinamide)20$15,635
SynjardyEmpagliflozin/Metformin Hcl14$14,151
Tresiba Flextouch U-200Insulin Degludec20$14,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$500$317,716226 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy$142$230,185213 claims
Lilly USA, LLCTrulicity, Mounjaro, Baqsimi$58$181,373161 claims
AstraZenecaFarxiga$142$26,19424 claims
MerckJanuvia$16$19,78412 claims
AbbVieSynthroid$38$10,261115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →